P1067: ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA

• Philippe Armand,
• Pier Luigi Zinzani,
• John Timmerman,
• Nathalie Johnson,
• David Lavie,
• Kannan Thiagarajan,
• Brian Topp,
• Pallavi Pillai,
• Alex F. Herrera

Affiliations

Philippe Armand

1 Dana-Farber Cancer Institute, Boston, United States

Pier Luigi Zinzani

2 IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy

John Timmerman

3 UCLA Medical Center, Los Angeles, United States

Nathalie Johnson

4 Jewish General Hospital, Montréal, Canada

David Lavie

5 Hadassah Medical Center, Jerusalem, Israel

Kannan Thiagarajan

6 Merck & Co., Inc., Rahway, United States, and under contract with Vantage Research Inc., Chennai, India

Brian Topp

7 Merck & Co Inc, Rahway, United States

Pallavi Pillai

7 Merck & Co Inc, Rahway, United States

Alex F. Herrera

8 City of Hope, Duarte, United States